- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03418025
Exercising Together During Radiation Treatment
Exercising Together: An Intervention for Couples Coping With Prostate Cancer During Radiation Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. Determine the feasibility and acceptability of offering the Exercising Together program to couples during the time when men are undergoing an 8 week radiation treatment regimen.
SECONDARY OBJECTIVES:
I. Examine the efficacy of partnered strength training on objective physical function, self-report function, symptoms and intimacy in both the patient and his spouse.
OUTLINE:
All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.
EXERCISING TOGETHER PROGRAM: Participants complete three exercise sessions (approximately 1 hour per session) per week over 5-8 weeks during radiation treatment. Participants also receive a digital video disc (DVD) of a partnered strength training exercise program to continue on their own after radiation is completed.
After completion of the supervised exercise program, participants are followed up at 8 weeks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- OHSU Knight Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- PATIENTS
- Histologically confirmed prostate cancer (confirmed by self-report on Health History Questionnaire)
- Scheduled to receive a course (5-8 weeks) of radiation treatment for prostate cancer at Oregon Health & Science University (OHSU) Department of Radiation Medicine (confirmed by self-report on Health History Questionnaire)
- Currently residing with an identifiable spouse (or co-residing partner) willing to participate (confirmed by self-report on Health History Questionnaire)
- SPOUSES
- Currently residing with the prostate cancer patient (confirmed by self-report on Health History Questionnaire)
Exclusion Criteria:
- Cognitive difficulties that preclude answering the survey questions or giving informed consent
- Medical condition, movement or neurological disorder, or medication that contraindicates participation in resistance exercise (for patient: confirmed by email and/or Electronic Privacy Information Center [EPIC] by Dr. Hung; for spouse: must answer 'No' to exercise pre-participation screening questions (question #20 & #21) in Health History Questionnaire (HHQ); if spouse answers 'Yes' to either question they will be considered eligible upon physician clearance; the exercise pre-participation screening questions are based on the American College of Sports Medicine 2016 Exercise pre-participation screening criteria)
- Currently participating in partnered strength training 2 or more times per week (confirmed by self-report on the Godin Leisure Time Exercise Questionnaire)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group I (Exercising Together program)
Exercise Intervention. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment. EXERCISING TOGETHER PROGRAM: Participants complete three exercise sessions (approximately 1 hour per session) per week over 5-8 weeks during radiation treatment. Participants also receive a DVD of a partnered strength training exercise program to continue on their own after radiation is completed. |
Ancillary studies
Ancillary studies
Undergo Exercise Together intervention
|
|
Active Comparator: Group II (pre and post testing)
Questionnaire Administration & Survey Administration.
All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment.
The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.
|
Ancillary studies
Ancillary studies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility
Time Frame: Up to 8 weeks post radiation treatment
|
Will be determined as the number of couples who enroll out of those approached and the number of couples who opt to participate in Exercising Together versus to participate as controls.
Will evaluate using descriptive statistics.
|
Up to 8 weeks post radiation treatment
|
|
Physical function
Time Frame: Up to 8 weeks post-radiation treatment
|
Will be measured by the Physical Performance Battery (PPB), developed for the Established Populations for Epidemiologic Studies of the Elderly study.
The PPB consists of three timed tests: 5 repeated chair stands, standing balance, and gait speed over 4 meters.
Each test is scored 0 (unable) to 4, based on quartiles of performance, then scores are summed.
Higher scores indicate better physical function.
|
Up to 8 weeks post-radiation treatment
|
|
400m walk Test
Time Frame: Up to 8 weeks post-radiation treatment
|
The 400m walk test is a self-paced, submaximal exercise test.
Participants will be required to move as fast as they can along a 20m course, demarked by two cones, until they have completed 10 laps of the course (400m).
The time taken to complete the test will be recorded.
|
Up to 8 weeks post-radiation treatment
|
|
Acceptability
Time Frame: Up to 8 weeks post-radiation treatment
|
Will be measured by the average attendance at classes over the course of his radiation therapy.
This will be calculated as the total number of classes attended divided by the total possible they could attend over the course of radiation therapy.
Attendance will be categorized by sessions couples attended together and those where only one partner attends.
Will evaluate using descriptive statistics.
|
Up to 8 weeks post-radiation treatment
|
|
Depressive symptoms
Time Frame: Up to 8 weeks post-radiation treatment
|
Will be measured with the Center for Epidemiological Studies-Depression (CES-D) scale.
Scores range from 0-60, with higher scores indicating > depressive symptomology.
|
Up to 8 weeks post-radiation treatment
|
|
Anxiety
Time Frame: Up to 8 weeks post-radiation treatment
|
Will be measured from the Symptom Checklist - 90 Anxiety Scale (SCL-90 ANX) which includes 10 items representing anxiety symptoms, scored on a 5 point scale ranging from 0 (not at all) to 4 (extremely).
|
Up to 8 weeks post-radiation treatment
|
|
Physical intimacy
Time Frame: Up to 8 weeks post-radiation treatment
|
Physical intimacy behavior of patient and spouse will be measured using the Physical intimacy behavior scale.
Respondents are asked to report the frequency with which they engage in, initiate and avoid each of four affectionate and two sexual behaviors.
Three scales assess the frequency, initiation and avoidance of affectionate and sexual behaviors.
|
Up to 8 weeks post-radiation treatment
|
|
Strain
Time Frame: Up to 8 weeks post-radiation treatment
|
Spouse strain will be measured with the role overload scale, which assesses the extent a spouse's time and energy are exhausted by demands of care for their partner.
|
Up to 8 weeks post-radiation treatment
|
|
Dyadic coping
Time Frame: Up to 8 weeks post-radiation treatment
|
Two types of dyadic coping will be measured.
Active engagement assesses the extent to which the survivor (SVR) and spouse view their partner's active involvement and joint problem-solving.
Participants respond to five items using a Likert scale from 1 (never) to 5 (very often).
Higher scores indicate higher levels of perceived active engagement.
Protective buffering assesses the extent to which the SVR and spouse view their partner's use of hiding concerns and denying worries.
Participants respond to six items using a Likert scale from 1 (never) to 5 (very often).
Higher scores indicate higher levels of perceived protective buffering.
|
Up to 8 weeks post-radiation treatment
|
|
Exercise outside the exercise intervention
Time Frame: Up to 8 weeks post-radiation treatment
|
Will measure outside activity with the Modified Godin Leisure-Time Exercise Questionnaire (GLTEQ).
This survey, reported in average minutes per week over the past month, will be broken down into four categories: mild effort (minimal effort), moderate exercise (not exhausting), and strenuous exercise (heart beats rapidly), as well as resistance (weight bearing exercise).
The questionnaire will be scored three different ways, to better capture different aspects of PA: 1) total activity = vigorous + moderate + mild + resistance 2) physical activity guidelines = moderate + (vigorous x 2) 3) moderate + vigorous.
|
Up to 8 weeks post-radiation treatment
|
|
Subjective evaluation of Exercising Together Program
Time Frame: Up to 8 weeks post-radiation treatment
|
For couples who opt to participate in Exercising Together will also ask them to fill out a survey asking about their experience in the program.
They will be asked to rate their overall experience in the exercise classes using a 1 to 10 likert scale with 1 being poor and 10 being exceptional as well as indicate how much they agree or disagree with perceptions of the class.
|
Up to 8 weeks post-radiation treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00017367
- NCI-2018-00031 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- CPC-17135-L (Other Identifier: OHSU Knight Cancer Institute)
- IRB00017367 (Other Identifier: OHSU Insitutional Review Board)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Carcinoma
-
M.D. Anderson Cancer CenterJanssen PharmaceuticaActive, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Oligometastatic Prostate CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingCastration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Refractory Prostate Carcinoma | Metastatic Castration-Resistant Prostate CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedMetastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityActive, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Castration Levels of Testosterone | Stage IV Prostate AdenocarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate CancerUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Thomas...Novartis; Prostate Cancer Clinical Trials ConsortiumTerminatedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7 | Prostate Carcinoma Metastatic in the BoneUnited States
-
Mayo ClinicCongressionally Directed Medical Research ProgramsRecruitingBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Locally Advanced Prostate CarcinomaUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8United States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Istanbul Aydın UniversityCompleted
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Université Catholique de LouvainRecruiting
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingCOVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingEndometrial Carcinoma | Malignant Uterine Neoplasm | Uterine Corpus Cancer | Uterine Corpus SarcomaUnited States
-
Ohio State University Comprehensive Cancer CenterNational Center for Complementary and Integrative Health (NCCIH)CompletedBreast Cancer | Prostate CancerUnited States